Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

Report Highlights

The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.

Report Includes

• An overview of the global markets for liquid biopsy research tools, services, and diagnostics
• Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
• Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
• Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, and research tools reagents
• Breakdowns of the market by product, product type, application, end use industry, technology, and indication
• Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
• Profiles of major players in the industry

Report Scope

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies.The market sizes for liquid biopsy diagnostics are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy.It then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development.Market driving forces are also discussed.

The structure of several important industry subsectors is reviewed, as well as major industry acquisitions and strategic alliances from January 2016 through July 2017.Industry subsectors analyzed includenext-generation sequencing(NGS) instruments, droplet digital PCR, target enrichment and amplification, single-cell DNA polymerase, prenatal screening, liquid biopsy, direct to consumer, and clinical laboratory.

The market for liquid biopsy diagnostics is analyzed in depth.The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia-Pacific, Rest of World).

Market data cover the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

More than 165 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2016 through July 2017, including key alliance trends.

Analyst Credentials

John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.

Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.